Table 1 Observed and expected numbers of cancers, SIRs, and 95% CIs among PWHA by period of cancer diagnosis

From: Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study

 

Period

 

Pre-HAART (1985–1996) 20 615 PY

Early-HAART (1997–2001) 17 690 PY

Late–HAART (2002–2006) 15 410 PY

Cancer site or type (ICD10)

O/E

SIR

95% CI

O/E

SIR

95% CI

O/E

SIR

95% CI

AIDS-defining cancers

 Kaposi's sarcoma (C46)

272/1.1

246

218–277

35/0.7

47.8

33.3–66.6

14/0.6

22.9

12.5–38.5

 Non-Hodgkin's lymphoma (C82-C88, C96)

191/1.9

103

88.8–119

52/1.9

26.7

19.9–35.1

32/2.0

16.2

11.1–22.9

 Cervix uteri (C53)

4/0.5

8.4

2.2–21.8

2/0.5

3.7

0.3–13.6

0/0.5

—

—

 All AIDS-defining cancers

467/3.4

136

124–149

89/3.2

27.7

22.2–34.1

46/3.1

14.7

10.8–19.6

Non-AIDS-defining cancers

 Head and neck (C00-C14, C30-C32)a

9/2.1

4.3

2.0–8.3

8/2.7

2.9

1.3–5.8

7/3.2

2.2

0.9–4.5

 Stomach (C16)

1/0.7

1.5

0.0–8.5

1/0.9

1.2

0.0–6.7

1/1.0

1.0

0.0–5.6

 Small intestine, colon, rectum and rectosigmoid junction (C17-C20)

2/1.8

1.1

0.1–4.0

2/2.8

0.7

0.1–2.6

1/3.5

0.3

0.0–1.6

 Anus (C21)

2/0.1

25.7

2.4–94.5

12/0.1

112

57.8–197

6/0.1

49.9

18.0–109

 Liver (C22)

2/0.4

5.5

0.5–20.2

7/0.7

10.7

4.2–22.2

5/0.8

6.1

1.9–14.3

 Pancreas (C25)

0/0.4

—

—

2/0.6

3.4

0.3–12.4

1/0.7

1.4

0.0–7.8

 Trachea, lung and bronchus (C33, C34)

8/2.4

3.3

1.4–6.6

10/3.6

2.8

1.3–5.1

12/4.6

2.6

1.3–4.6

 Skin, melanomatous (C43)

3/2.5

1.2

0.2–3.5

2/3.1

0.6

0.1–2.4

6/3.1

2.0

0.7–4.3

 Skin, non-melanomatous (C44)

7/4.0

1.7

0.7–3.6

23/6.5

3.5

2.2–5.3

23/7.0

3.3

2.1–4.9

 Breast (C50)b

1/1.7

0.6

0.0–3.4

4/3.3

1.2

0.3–3.2

4/4.3

0.9

0.2–2.4

 Ovary (C56)

2/0.3

6.4

0.6–23.5

0/0.4

—

—

0/0.5

—

—

 Prostate (C61)

0/1.1

—

—

5/2.8

1.8

0.6–4.1

5/3.8

1.3

0.4–3.1

 Testis (C62)

4/3.0

1.3

0.3–3.4

3/2.4

1.2

0.2–3.7

1/1.8

0.5

0.0–3.1

 Kidney (C64)

1/0.5

1.9

0.0–10.6

1/0.8

1.3

0.0–7.2

3/1.0

3.1

0.6–9.2

 Bladder (C67)

1/1.0

1.1

0.0–6.0

0/1.4

—

—

1/1.7

0.6

0.0–3.3

 Brain, meninges and central nervous systems (C70-C72)

2/0.9

2.2

0.2–7.9

2/0.9

2.2

0.2–8.0

0/1.0

—

—

 Thyroid (C73)

2/0.7

2.9

0.3–10.7

1/0.8

1.2

0.0–7.0

0/0.8

—

—

 Hodgkin's lymphoma (C81)

7/0.8

9.2

3.6–19.0

12/0.6

21.0

10.8–36.8

13/0.5

28.1

14.9–48.2

 Multiple myeloma (C90)

3/0.2

14.8

2.8–43.9

1/0.3

3.2

0.0–18.1

2/0.4

5.1

0.5–18.9

 Leukaemias (C91-C95)

1/0.7

1.5

0.0–8.3

2/0.8

2.4

0.2–8.8

1/0.9

1.1

0.0–6.5

 All non-AIDS-defining cancersc

62/26.7

2.3

1.8–3.0

100/37.3

2.7

2.2–3.3

94/42.8

2.2

1.8–2.7

All cancers

529/30.1

17.6

16.1–19.1

189/40.6

4.7

4.0–5.4

140/46.0

3.0

2.6–3.6

  1. Abbreviations: CI=confidence intervals; E=expected; HAART=highly active antiretroviral therapy; O=observed; PWHA=people with HIV or AIDS; PY=person years; SIRs=standardised incidence ratios.
  2. aIncludes nine tongue, six mouth, three larynx cancers, and one cancer each of lip, tonsil, oropharynx, nasopharynx, hypopharynx, and nasal cavity.
  3. bFemales only.
  4. cAlso includes four unknown primary sites plus one cancer each of the oesophagus, biliary tract, connective/soft tissue, and corpus uteri.
Back to article page